Trevi Therapeutics’ (TRVI) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research note issued to investors on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $21.00 price objective on the stock.

Several other research firms have also issued reports on TRVI. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $9.00 to $29.00 in a research note on Monday, March 10th. Needham & Company LLC cut their price objective on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday. Oppenheimer increased their target price on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. Finally, HC Wainwright lifted their price target on shares of Trevi Therapeutics from $7.50 to $12.50 and gave the stock a “buy” rating in a report on Monday, March 10th. Seven equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $17.56.

Trevi Therapeutics Stock Performance

NASDAQ TRVI opened at $6.47 on Wednesday. The company has a market cap of $497.32 million, a PE ratio of -14.70 and a beta of 0.90. The firm’s 50 day moving average price is $4.60 and its 200-day moving average price is $3.75. Trevi Therapeutics has a 52-week low of $2.30 and a 52-week high of $7.39.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01. On average, analysts forecast that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Trevi Therapeutics

In other news, insider Farrell Simon sold 81,313 shares of Trevi Therapeutics stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the sale, the insider now directly owns 76,900 shares in the company, valued at approximately $519,075. The trade was a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 24.37% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Trevi Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. grew its stake in Trevi Therapeutics by 44.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock valued at $43,939,000 after purchasing an additional 3,283,684 shares during the last quarter. Woodline Partners LP lifted its holdings in shares of Trevi Therapeutics by 429.9% during the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock worth $13,236,000 after purchasing an additional 2,606,370 shares during the period. Squarepoint Ops LLC acquired a new position in Trevi Therapeutics in the 4th quarter worth approximately $58,000. Two Sigma Advisers LP acquired a new position in Trevi Therapeutics in the 4th quarter worth approximately $66,000. Finally, Two Sigma Investments LP acquired a new position in Trevi Therapeutics in the 4th quarter worth approximately $560,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.